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Objective: The purpose of this study was to develop a practical and scientifically rigorous, patient-reported outcome
measure to evaluate quality of life and symptoms across the range of conditions (eg, telangiectasias, varicose veins, edema,
skin changes, leg ulcers) in chronic venous disorders of the leg (CVDL).
Methods: This study was a psychometric study within the VEnous INsufficiency Epidemiological and Economic Study
(VEINES), an international, prospective cohort study to evaluate clinical outcomes, quality of life, costs, and use of health
services in CVDL. The study was set in the 166 general practices and 116 specialist clinics in Belgium, France, Italy, and
Canada (Quebec) that participated in the VEINES study plus in additional specialist clinics in Ottawa and Montreal.
Field testing was carried out in three samples of patients in four countries (Belgium, France, Italy, Canada), including
participants in the VEINES study (n  1531) and patients recruited in additional samples of 88 English-speaking
patients (Canada) and 53 French-speaking patients (Belgium, France). The reliability and validity sample (n  615)
included 527 VEINES patients and 88 patients from the supplementary English-speaking sample. The test-retest sample
(n  135) included 53 French-speaking and 82 English-speaking patients from the supplementary samples. The
responsiveness sample included 1516 VEINES patients. The 26-item VEINES-QOL/Sym is a new, patient-reported
questionnaire to evaluate symptoms and quality of life and is available in four language versions (English, French, Italian,
French Canadian).
Results: Standard psychometric tests confirmed the acceptability (missing data, item endorsement frequencies, floor and
ceiling effects), reliability (internal consistency, item-total, inter-item correlations) and validity (content, construct,
convergent, discriminant, known groups) of the four language versions of the VEINES-QOL/Sym and the test-retest
reliability of the English and French versions and provided preliminary evidence of responsiveness in a pooled language
sample.
Conclusion: The VEINES-QOL/Sym is a practical and scientifically sound, patient-reported measure of outcomes in
CVDL that has been developed with rigorous methods. As the only fully validated measure of quality of life and
symptoms that is appropriate for use across the full spectrum of CVDL-related conditions, that is quick and easy to
administer, and that is available in four languages, the VEINES-QOL/Sym provides a rigorous tool for improving the
evaluation of outcomes in clinical trials, epidemiologic studies, and audit. (J Vasc Surg 2003;37:410-9.)
Chronic venous disorders of the leg (CVDL) is an
umbrella term that encompasses a variety of clinical presen-
tations of chronic venous insufficiency. These presentations
include venous symptoms (eg, leg swelling, pain, heavi-
ness), telangiectasias, varicose veins, edema, skin changes,
and leg ulcers.1,2 CVDL is common in the general popula-
tion,2-4 and its rate is likely to increase because of popula-
tion aging.5 The direct costs of CVDL are high because of
its prevalence, morbidity, and chronicity.1,2,6-8 Substantial
indirect costs are also associated with the pain, disability,
and distress that characterize CVDL and have a detrimental
impact on quality of life.2
Treatments for CVDL1,9 have generally been evaluated
solely on the basis of clinical outcomes (eg, signs, symp-
toms, laboratory tests, and clinical judgments of treatment
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efficacy, adverse reactions, and compliance1,2). A limitation
of clinical outcome measures is that they do not directly
capture the burden of CVDL or patients’ views of impact
on quality of life and symptoms. Because patient-reported
outcomes are considered a key component in assessment of
outcomes,10 it is important that new treatments are evalu-
ated with scientifically rigorous measures of quality of life
and symptoms that are reliable, valid, and responsive.2,11
Generic quality-of-life measures, intended for use
across different diseases, permit cross-study comparisons
and enhance generalizability, whereas disease-specific mea-
sures, developed for use in a specific condition to target
disease-associated effects, are more responsive in detection
of treatment effects.12 The most commonly used generic
measure in CVDL is the SF-36, which has been used to
assess outcome in varicose veins13-15 and leg ulcers.16-18
Other generic measures include the Nottingham Health
Profile, used in four studies of leg ulcer,17-21 and the
EuroQol, used in a study of ulcers.17 The strength of
generic measures is that all are scientifically rigorous mea-
sures with proven psychometric properties (ie, reliability,
validity, responsiveness). However, generic measures do
not give a full picture of the impact of CVDL per se on
quality of life. Moreover, previous studies that have used
generic measures have investigated quality of life in varicose
veins or leg ulcers and not the full spectrum of CVDL.
Disease-specific scales have also been used to evaluate
quality of life, but only three of these were developed for
use across the range of CVDL-related conditions. Of these,
one has not been adequately evaluated for reliability, valid-
ity, and responsiveness,22 and two have not been validated
in English.23,24 In addition to these all purpose measures
that are appropriate for use across the full spectrum of
CVDL-related conditions, three measures have been devel-
oped exclusively for use in leg ulcers18,25,26 and one in
varicose veins.13,15 Only two of these condition-specific
measures show good psychometric properties and can be
recommended for use in evaluating quality of life in ulcers18
or varicose veins.13,15
Symptom scales fare poorly in terms of scientific credi-
bility. Four scales have been used to evaluate patient-
reported symptoms, including three for use across the
range of CVDL-related conditions27-30 and one for vari-
cose veins.31 All assess standard CVDL symptoms (eg, pain,
heaviness, fullness, swelling, discomfort, itching, cramps,
aching legs, sensation of heat/burning, restless legs, pares-
thesias, tired legs, skin irritation, discomfort during pro-
longed standing/sitting, and the urge to elevate the legs)
but differ in the number of symptoms measured, how these
are rated, and whether summary scores are used. Some
scales, for example, measure only a few key symptoms,
whereas others assess several symptoms. Some evaluate
symptoms with global ratings, whereas others use quanti-
tative categoric or visual analogue scales. Some scales pro-
vide scores for individual symptoms, whereas others pro-
vide summary scores or symptom indexes. The most
important limitation of all these scales is that none have
been fully evaluated for reliability, validity, and responsive-
ness. Without evidence of their psychometric properties,
none of the currently available measures of symptoms can
be considered to be adequately scientifically robust for use
in research or clinical practice.
Evidence from the literature1 and expert opinion2 con-
firm the need for a scientifically rigorous measure, which is
appropriate across the full spectrum of CVDL-related con-
ditions, to evaluate patient-reported outcomes in clinical
trials, epidemiologic studies, and audit. We describe the
development and validation of the VEnous INsufficiency
Epidemiological and Economic Study (VEINES)–QOL/
Sym, a new, patient-reported measure of quality of life and
symptoms in CVDL. We used rigorous psychometric
methods32 to guide the development and evaluation of the
VEINES-QOL/Sym. These standard scientific methods,
borrowed from the social sciences for application in health-
care,33 allow regulatory bodies, clinicians, researchers, and
patient advocacy groups to determine whether an instru-
ment is a “good” measure that provides scientifically cred-
ible information. Psychometrics provide well-established
scientific methods for measurement of subjective judg-
ments with numeric scales and for evaluation of the quality
of measurement scales (ie, acceptability, reliability, validity,
responsiveness). Rigorous criteria are now available for
evaluation of the scientific robustness of patient-reported
health outcome measures34,35 and have been applied in
several areas of medicine and surgery.36-38 We developed
and undertook a thorough psychometric evaluation of the
VEINES-QOL/Sym questionnaire as part of the VEINES
study, an international, prospective, cohort study to evalu-
ate epidemiology (natural history, risk factors) and out-
comes (clinical outcomes, quality of life, costs, health ser-
vice use) in CVDL.
PATIENTS AND METHODS
Questionnaire development
Development of questionnaire content. We used
the following three sources of information to develop the
content of the questionnaire: 1, findings from the literature
review of patient-reported outcomes in CVDL1,11; 2, a
review of existing measures of outcome in CVDL; and 3,
expert clinical opinion about the problems commonly re-
ported by patients with CVDL.2 We developed a concep-
tual model of patient-reported outcomes in CVDL that
included two content domains: quality of life and symp-
toms. We then generated questionnaire items for both
domains through consensus discussions with a multidisci-
plinary expert group of clinicians and methodologists with
expertise in CVDL, questionnaire design, psychometrics,
and epidemiology. The content and format of question-
naire items and response scales were modeled after the
SF-36.39,40 We modified generic SF-36 questions to make
them specific to CVDL and developed new CVDL-specific
questions with the same format and response scales of the
SF-36. The draft questionnaire was developed in English.
Translation and expert review. Members of the ex-
pert group revised the content and format of the English
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version of the questionnaire through a formal, independent
review of several drafts of the questionnaire. Modifications
were made to ensure clarity, consistency, and clinical rele-
vance. The questionnaire then was translated into French
(for use in Belgium and France) with standard translation-
backtranslation procedures.41,42 Both the English and
French versions were again independently reviewed by the
expert group. Final modifications were made, and the
questionnaire then was translated into Italian and French
Canadian (for use with French-speaking patients in Cana-
da).
Pre-testing with patients. The preliminary versions
of the questionnaire were pre-tested by face-to-face inter-
view with a small sample of consecutive patients, selected by
one of the study clinicians in each country, to clarify ambi-
guities in wording, to confirm the appropriateness of re-
sponse scales, and to determine acceptability and comple-
tion time. Modifications to the questionnaires then were
made, and final translations agreed.
VEINES-QOL/Sym questionnaire
The 26-item VEINES-QOL/Sym (Appendix, online
only) measures the impact of CVDL on symptoms and
quality of life from the patient’s perspective. Twenty-one
items cover symptoms (10 items), limitations in daily activ-
ities (9 items), time of day of greatest intensity (1 item), and
change over the past year (1 item), and five items cover
psychological impact. Responses are rated on 2-point to
7-point response scales of intensity, frequency, or agree-
ment. The time frame for questions about symptoms, daily
limitations, and psychological impact is the past 4 weeks, as
in the SF-36. The VEINES-QOL/Sym is a patient-based
questionnaire that is designed for self completion.
Two summary scores can be computed. The VEINES-
QOL summary score (25 items) provides an estimate of the
overall impact of CVDL on the patient’s quality of life. The
VEINES-Sym summary score (10 items) measures symp-
tom severity. This score includes nine CVDL symptoms
(heavy legs, aching legs, swelling, night cramps, heat or
burning sensation, restless legs, throbbing, itching, tin-
gling sensation), rated on a 5-point scale of frequency (1,
every day; 2, several times a week; 3, about once a week; 4,
less than once a week; 5, never), and leg pain, rated on a
6-point scale of intensity (1, none; 2, very mild; 3, mild; 4,
moderate; 5, severe; 6, very severe; reverse scored). One
item (Q2) regarding the time of day that the leg problem is
most intense is not included in the summary scores; it
provides descriptive information only, which may be of use
in epidemiologic research. Three items (Q3, Q6, Q7) are
reversed scored so that for both the VEINES-QOL and
VEINES-Sym scales, high scores indicate better outcomes.
Because questionnaire items have a varying number of
response categories, it is not valid to simply sum items to
create summary scores. The VEINES-QOL/Sym uses the
standard method for scoring questionnaires with items with
different response scales33 that is now routinely used.43
Raw scores are first transformed to z score equivalents
(mean, 0; standard deviation, 1), which then are trans-
formed to T scores (mean, 50; standard deviation, 10) to
give an easily understood range of scores. Scores for missing
data are imputed with the same algorithm recommended
for scoring the SF-36.39,40 A person-specific estimate is
imputed for any missing item in cases where the patient
answered at least 50% of the items in the scale. A comput-
erized scoring program is also available.
VEINES study
The VEINES study is an international, prospective
cohort study that evaluated epidemiology (natural history
and risk factors) and outcomes (clinical outcomes, quality
of life, costs and use of health services) in CVDL.44,45
Sampling of the study population was based on a prospec-
tive registration of 5688 consecutive outpatients from 18
to 75 years of age who consulted 166 general practitioners
and 116 specialists (vascular surgeons, phlebologists, angi-
ologists) in four countries. Registered patients at each
clinical site were organized into a sampling frame in which
all male patients and patients with ulcers were at the top of
the list, followed by all other registered patients in random
order. Study coordinators then randomly selected study
patients from the registered patient sampling frame until
target sample sizes were achieved. Male patients and pa-
tients with ulcers were deliberately oversampled. A total of
1531 patients, randomly selected from all registered pa-
tients, agreed to participate in the VEINES study (n 484
in Belgium, n 593 in France, n 359 in Italy, n 95 in
Canada). Of these, 947 patients were recruited by general
practitioners and 584 by specialists. Ethics approval was
obtained from the relevant committees in each country,
and written informed consent was obtained from all pa-
tients before study entry.
Clinical outcomes were assessed at clinical visits at
baseline and at 3-month (range, 2 to 6 months) and 12-
month follow-up. These included four outcomes evaluated
with clinical examination (disease severity, varicose veins,
varicose vein–related pain, and edema, defined as pitting
edema, and objectively measured edema, assessed with a
standardized tape measure device, the Leg-O-Meter).46
For each of the five clinical outcomes, patients were classi-
fied as clinically improved or unimproved (no change,
worse) at each follow-up visit. Ulcers also were assessed in
the clinical examination, but improvement in this clinical
outcome was not included in the psychometric analyses
reported in this paper because of insufficient numbers.
Disease severity was assessed with the CEAP system47 (0,
no visible or palpable signs of venous disease; 1, telangiec-
tasia or reticular veins; 2, varicose veins; 3, edema; 4, skin
changes from venous disease; 5, skin changes with healed
ulceration; 6, skin changes with active ulceration). Patients
with symptoms alone (eg, heavy legs), without any visible
or palpable signs of venous disease but judged by study
clinicians to have a possible venous origin, were included in
CEAP category 0.
We assessed patient-reported symptoms and quality of
life at the same three assessment points with the appropriate
language versions of the VEINES-QOL/Sym and
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SF-36.39,40 The SF-36 produces two summary scores: a
Physical Component Summary score (PCS) and a Mental
Component Summary score (MCS). At baseline, patients
completed both questionnaires via postal survey before the
clinic visit. At follow-up assessments, questionnaires were
given to patients at the clinic visit with instructions to
complete them at home and return via post.
Psychometric evaluation of the VEINES-QOL/Sym
We evaluated the psychometric properties of the
VEINES-QOL/Sym in extensive field testing in three sam-
ples of patients, including 1516 patients from the VEINES
study plus additional samples of 88 English-speaking pa-
tients in Canada and 53 French-speaking patients in Bel-
gium and France. We also recruited two supplementary
convenience samples from specialist clinics in Canada, Bel-
gium, and France to: 1, evaluate the English version of the
questionnaire (because only 15 English-speaking patients
were included in the VEINES study); and 2, evaluate the
test-retest reliability of the English and French versions of
the questionnaire.
Reliability and validity sample. Reliability and valid-
ity analyses were carried out in a sample of 615 of 657
patients (94%) who provided scorable VEINES-QOL/
Sym questionnaires (20% or less missing data). The sample
included 88 English-speaking patients recruited through
specialists in Canada (Ottawa and Montreal) and 527 pa-
tients recruited through specialists in the VEINES study
(305 French speakers, including 201 patients from France
and 98 patients from Belgium, 143 Italian speakers, and 79
French-Canadian speakers).
Test-retest reliability sample. Test-retest reliability
was evaluated for the English and French versions in 53
French-speaking patients, recruited through specialists in
Belgium (n 25) and France (n 28), and in 82 of the 88
English-speaking patients (93%), recruited through special-
ists in Canada. Patients completed the VEINES-QOL/
Sym via postal survey on two occasions separated by a
14-day to 30-day interval. Six English-speaking patients
who did not complete the retest within the specified inter-
val were excluded from the test-retest sample.
Responsiveness sample. Responsiveness was evalu-
ated in the pooled sample of 1516 of 1531 patients in the
VEINES study (excluding 15 English-speaking patients).
Because evaluation of the responsiveness for individual
language versions was not possible because of insufficient
sample sizes, we used the same approach to perform anal-
yses on pooled data that has been used in previous psycho-
metric validations of other commonly used international
outcome measures.48 We were unable to evaluate the re-
sponsiveness of the English-language version. Only 15
English-speaking patients were included in the VEINES
study, and in the supplementary sample of 82 English-
speaking patients, responsiveness data were not collected.
The pooled sample for the responsiveness analyses in-
cluded 484 patients recruited in Belgium, 593 in France,
359 in Italy, and 80 in Canada (excluding 15 English-
speaking patients) who were recruited by specialists (n 
569) and general practitioners (n  947). Patients were
included in the responsiveness analyses if they satisfied the
following three criteria: 1, less than 20% missing data on the
VEINES-QOL/Sym; 2, data available for at least two
assessment points for both patient-reported and clinical
outcomes; and 3, one of the target clinical conditions used
in the responsiveness analyses (eg, varicose veins or edema)
or a CEAP score. The third criterion was necessary for
evaluation of improvement in clinical condition during the
follow-up period.
We used standard psychometric tests and criteria (Table
I) to evaluate the acceptability, reliability, validity, and
responsiveness of VEINES-QOL/Sym scores.
RESULTS
Respondent characteristics
Table II shows the characteristics of patients in the
reliability and validity sample. Most of the sample was
female. The proportion of women was highest in the En-
glish-speaking (Canadian) and French-speaking (France)
samples. Respondents ranged in age from 23 to 75 years
(mean age range, 46 to 53 years). Respondents were on
average oldest in the Italian sample and youngest in the
French-Canadian sample. A higher proportion of patients
in the English-speaking (Canadian) sample were in CEAP
class 2 (varicose veins), and a lower proportion in CEAP
classes 1 (telangiectasia or reticular veins) and 4 (skin
changes). Higher proportions of patients in the Italian
sample were in CEAP class 3 (edema) and in the French-
speaking (Belgium) sample in CEAP class 5 (skin changes
with healed ulceration). Table III shows the age and gender
of respondents in the responsiveness sample. Over three
quarters of the sample were women. Respondents ranged in
age from 20 to 75 years (mean, 54 years).
Psychometric properties
Results are reported separately for VEINES-QOL and
VEINES-Sym scores for each of the four language versions.
Results for the French language version are reported sepa-
rately for Belgium and France.
Acceptability. All four language versions show good
acceptability. Pre-testing indicated that the questionnaire
took less than 10 minutes to complete. Table IV shows a
low proportion of missing data and low floor/ceiling ef-
fects. Examination of item endorsement frequencies (re-
sults not shown) showed that responses were well distrib-
uted across response categories.
Internal consistency reliability. As shown in Table
IV, Cronbach’s49  coefficients indicate high internal con-
sistency for all four language versions. Values exceed the
standard criterion of 0.70. All item-total correlations satis-
fied the criterion of more than 0.20, ranging from 0.21 to
0.79 for the VEINES-QOL and from 0.22 to 0.82 for the
VEINES-Sym.
Test-retest reliability. As shown in Table IV, both
the English-language and French-language versions show
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Table I. Psychometric tests and criteria
Psychometric property Definition/test Criteria for acceptability
1. Acceptability Quality of data; assessed with completeness of data
and score distributions
Missing data for summary scores 5%
Even distribution of endorsement frequencies across
response categories
Floor/ceiling effects for summary scores 10%
2. Reliability
2.1 Internal consistency Extent to which items comprising scale measure
same construct (eg, homogeneity of scale);
assessed with Cronbach’s 48 and item-total
correlations.
Stability of measuring instrument; assessed with
administering instrument to respondents on
two different occasions and examining
correlation between test and retest scores*
Cronbach’s  for summary scores 0.7032
Item-total correlations 0.2032
2.2 Test-retest reliability Test-retest reliability correlations for summary scores
0.8032
3. Validity
3.1 Content validity Extent to which content of scale is representative
of conceptual domain it is intended to cover;
assessed qualitatively during questionnaire
development stage through pretesting with
patients, expert opinion, and literature review
Qualitative evidence from pre-testing with patients, expert
opinion, and literature review that items in scale are
representative of CVDL
3.2 Construct validity
3.2.1 Within-scale analyses Evidence that single entity (construct) is being
measured and that items can be combined to
form summary score; assessed on basis of
evidence of good internal consistency and
correlations between scale scores
Internal consistency (Cronbach’s ) 0.70
High correlation between VEINES-QOL and VEINES-
Sym scores (which purport to measure related aspects of
outcome)
3.2.2 Analyses against
external criteria
3.2.2.1 Convergent validity Evidence that scale is correlated with other
measures of same or similar constructs; assessed
on basis of correlations between
VEINES-QOL/Sym and SF-36 scores
Correlations are expected to vary according to similarity of
constructs being measured by each instrument. Specific
hypotheses are:
because both VEINES-QOL and SF-36 assess quality of
life, the two measures should be correlated
because VEINES-QOL and SF-36 differ in being disease-
specific versus generic, correlations are expected to be
in moderate range
because VEINES-QOL/Sym items tap more physical than
mental aspects, higher correlations are expected
between VEINES-QOL and SF-36 PCS (physical)
score than with MCS (mental) score
higher correlations are expected between VEINES-QOL
and SF-36 than between VEINES-Sym and SF-36
because there is less overlap in content between latter two
3.2.2.2 Discriminant
validity
Evidence that scale is not correlated with other
measures of different constructs; assessed on
basis of correlations with age and gender
Low correlations between VEINES-QOL/Sym scores and
age and gender
3.2.2.3 Known groups
differences
Ability of scale to differentiate known groups;
assessed with comparing VEINES-QOL/Sym
scores for patients who differ in severity of disease
VEINES-QOL/Sym scores should decrease (ie, poorer
quality of life, more frequent symptoms) with
increasing severity of disease across CEAP classes
4. Responsiveness Ability of scale to detect clinically important
change over time; assessed by comparing mean
scores for change in VEINES-QOL/Sym scores
from baseline to follow-up (t tests) in patients
with conditions defined as clinically improved
or unimproved during same period†,‡
Mean scores for change in VEINES-QOL/Sym scores
from baseline to follow-up should show improvement/
no improvement in patient conditions defined as
improved/unimproved according to: clinically
measured varicose veins, varicose vein-related pain, and
edema; objectively measured (Leg-O-Meter) edema;
CEAP scores
To compare responsiveness of disease-specific
VEINES-QOL/Sym with that of a generic
measure, we used same methods†,‡ to evaluate
responsiveness of SF-36 PCS and MCS scores
Mean scores for change in SF-36 scores from baseline to
follow-up should show improvement/no improvement
in patient conditions defined as improved/unimproved
according to: clinically measured varicose veins, varicose
vein-related pain, and edema; objectively measured
(Leg-O-Meter) edema; CEAP scores
*Length of test-retest interval must be short enough to ensure that clinical change in symptom being measured is unlikely to occur but sufficiently long to
ensure that respondents do not recall their responses from first assessment. Test-retest interval in this study was 14 to 30 days.
†Standard method for evaluating responsiveness is in context of intervention study where pretreatment/posttreatment change scores are used to determine
effect sizes. Because VEINES Study is cohort study with no systematic intervention component, we evaluated responsiveness by comparing change in
VEINES-QOL/Sym in patient conditions defined as clinically improved or unimproved according to five clinical outcomes.
‡Responsiveness analyses were performed on pooled data from all four countries/language versions because sample sizes for individual countries/language
versions were generally not sufficiently large to guarantee robustness of analyses. This approach to performing analyses on pooled data has been used in previous
psychometric validations of other commonly used international outcome measures.47
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good test-retest reliability. All intraclass correlation coeffi-
cients were more than 0.85.
Content validity. Content validity was evaluated dur-
ing the development of the questionnaire. Evidence from
pre-testing with patients, expert opinion, and a review of
literature supports the content validity of the VEINES-
QOL/Sym.
Construct validity (within-scale analyses). Evi-
dence of high internal consistency supports the construct
validity of the VEINES-QOL/Sym. High  coefficients
(Table IV) and moderately high item-total correlations
indicate that a single construct is being measured and that
the items can be combined to form summary scores. High
intercorrelations between VEINES-QOL and VEINES-
Table II. Respondent characteristics: reliability and validity sample (n  615)
English-speaking sample
(Canada; n  88)
French-speaking sample
(n  305)
Italian-speaking
sample (Italy;
n  143)
French Canadian–speaking
sample (Canada;
n  79)
France
(n  207)
Belgium
(n  98)
Female gender 92% 84% 76% 78% 73%
Age (y)
Range 28-77 20-75 23-75 23-75 23-74
Mean (standard deviation) 47.5 (12.1) 48.5 (13.1) 47.8 (12.8) 53.1 (12.7) 45.5 (11.8)
CEAP score
0 0.0% 3.9% 6.1% 6.3% 6.3%
1 2.3% 22.2% 22.4% 17.5% 31.6%
2 67.0% 23.7% 25.5% 19.6% 17.7%
3 8.0% 8.2% 5.1% 16.8% 6.3%
4 6.8% 32.9% 24.5% 32.9% 24.1%
5 0.0% 6.3% 11.2% 3.5% 6.3%
6 0.0% 1.9% 3.1% 1.4% 2.5%
Missing 15.9% 1.0% 2.0% 2.1% 5.1%
Table III. Respondent characteristics: responsiveness sample (n  1516)
Pooled sample
(n  1516)
French-speaking sample
(n  1077)
Italian-speaking
sample (Italy;
n  359)
French Canadian–speaking
sample (Canada;
n  80)
France
(n  593)
Belgium
(n  484)
Female gender 78% 80% 80% 71% 75%
Age (y)
Range 20-75 20-75 22-75 23-75 23-74
Mean (Standard deviation) 54.0 (13.8) 52.5 (14.5) 57.0 (13.3) 54.2 (12.7) 46.0 (12.0)
Table IV. Acceptability and reliability of VEINES-QOL/Sym
English-speaking
French-speaking
Italian-speaking
French
Canadian–speakingFrance Belgium
Missing data
VEINES-QOL 0% 1% 0% 4% 0%
VEINES-Sym 2% 2% 2% 3% 0%
Floor/ceiling effects (%)
VEINES-QOL 1/1 1/1 1/1 1/1 1/1
VEINES-Sym 1/6 1/2 1/4 1/3 1/6
Internal consistency (Cronbach’s )
VEINES-QOL 0.91 0.88 0.92 0.94 0.90
VEINES-Sym 0.87 0.82 0.88 0.87 0.87
Test-retest reliability (ICC)
VEINES-QOL 0.89 0.89* – –
VEINES-Sym 0.86 0.88 – –
*Test-retest data were collected in France and Belgium for French-language version.
ICC, Intraclass correlation coefficient.
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Sym scores (r 0.88, English; r 0.88, France; r 0.90,
Belgium; r  0.89, Italian; r  0.88, French-Canadian)
support the convergent validity of all four language versions
of the two scales.
Construct validity (convergent validity). Table V
shows correlations between the VEINES-QOL/Sym and
the SF-36. All correlations support hypotheses. The
VEINES-QOL/Sym is moderately correlated with SF-36
PCS and MCS summary scores. Second, correlations be-
tween the VEINES-QOL and SF-36 are higher for PCS
(physical) than MCS (mental) scores. Third, correlations
with the SF-36 are higher for the VEINES-QOL than the
VEINES-Sym.
Construct validity (discriminant validity). Low cor-
relations between the VEINES-QOL and VEINES-Sym
and age and gender (Table V; all correlations 0.25)
support the discriminant validity of both scales. These
results suggest that responses to the VEINES-QOL/Sym
are not biased in terms of age or gender.
Construct validity (known group differences). Ta-
ble VI presents mean VEINES-QOL/Sym scores for pa-
tients classified by CEAP scores. As hypothesized,
Table V. Convergent and discriminant validity of VEINES-QOL/Sym: correlations with other measures
English-speaking
French-speaking
Italian-speaking
French
Canadian–speakingFrance Belgium
VEINES-QOL
SF-36 physical (PCS) 0.61 0.52 0.69 0.73 0.71
SF-36 mental (MCS) 0.19 0.49 0.34 0.55 0.26
Age –0.22 –0.20 –0.18 –0.25 –0.11
Gender –0.11 0.02 0.07 –0.15 0.12
VEINES-Sym
SF-36 physical (PCS) 0.46 0.34 0.48 0.64 0.65
SF-36 mental (MCS) 0.15 0.37 0.24 0.42 0.21
Age –0.17 –0.09 –0.16 –0.20 –0.22
Gender –0.19 0.03 0.07 –0.16 0.24
Table VI. Known groups differences validity: mean VEINES-QOL/Sym scores by CEAP classification
CEAP
score† English-speaking
French-speaking
Italian-speaking
French
Canadian–speakingFrance Belgium
VEINES-QOL* 0 – 51.39 (3.7) 55.18 (7.9) 51.06 (7.2) 56.36 (2.9)
n  0 n  8 n  6 n  8 n  5
1 52.98 (6.1) 51.96 (5.4) 52.66 (5.0) 52.34 (5.0) 53.07 (4.9)
n  2 n  46 n  22 n  24 n  25
2 50.17 (6.0) 52.05 (4.7) 50.09 (6.1) 51.94 (6.3) 54.20 (3.4)
n  59 n  48 n  25 n  28 n  14
3 50.69 (7.1) 49.16 (3.6) 48.18 (4.4) 51.12 (6.7) 49.99 (5.8)
n  7 n  17 n  5 n  21 n  5
4 47.23 (3.1) 51.06 (4.8) 49.93 (6.3) 49.72 (7.0) 51.33 (6.6)
n  6 n  68 n  24 n  46 n  19
5 – 48.31 (5.7) 46.08 (3.4) 44.07 (5.4) 51.71 (3.5)
n  0 n  13 n  11 n  5 n  5
6 – 41.07 (4.9) 44.22 (4.2) 45.85 (2.9) 48.03 (2.5)
n  0 n  4 n  3 n  2 n  2
VEINES-Sym* 0 – 52.86 (4.8) 56.52 (6.4) 50.74 (6.4) 56.32 (4.2)
n  0 n  8 n  6 n  9 n  5
1 59.02 (--) 52.95 (6.6) 53.29 (6.6) 51.52 (5.9) 53.28 (5.5)
n  1 n  46 n  21 n  24 n  25
2 49.94 (7.1) 52.26 (5.5) 50.59 (6.4) 51.65 (6.7) 53.94 (4.6)
n  58 n  49 n  25 n  28 n  14
3 50.36 (8.7) 49.33 (3.7) 45.75 (6.5) 49.42 (8.2) 50.20 (6.1)
n  7 n  16 n  5 n  22 n  5
4 45.56 (5.8) 51.68 (5.2) 50.66 (7.2) 50.22 (7.1) 50.45 (8.1)
n  6 n  68 n  23 n  46 n  19
5 – 49.69 (6.0) 46.68 (4.0) 43.52 (8.2) 50.27 (4.9)
n  0 n  12 n  11 n  5 n  5
6 – 49.93 (3.5) 46.51 (3.6) 40.47 (10.3) 45.12 (8.3)
n  0 n  2 n  3 n  2 n  2
Numbers in brackets are standard deviations.
*Higher scores indicate better outcomes. Numbers are less than 615 due to missing data.
†Higher scores indicate more severe disease.
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VEINES-QOL and VEINES-Sym scores for each of the
four language versions show the expected gradient of
poorer outcome with increasing disease severity.
Responsiveness. Table VII shows mean change scores
for the VEINES-QOL/Sym and SF-36 and tests of differ-
ences between change in scores from the first to final
assessment for patients with conditions defined as clinically
improved or unimproved according to five clinical out-
comes. Results show that the VEINES-QOL and VEINES-
Sym are both highly responsive to clinical change but that
the SF-36 is much less responsive. For four of the five
clinical outcomes (change in clinically measured varicose
veins, varicose vein-related pain, clinically measured edema,
CEAP scores), the VEINES-QOL and VEINES-Sym suc-
cessfully discriminate between clinically improved and un-
improved conditions. By contrast, SF-36 PCS and MCS
scores only show responsiveness to change on one of five
clinical outcomes (change in CEAP scores and change in
varicose vein-related leg pain, respectively). For change in
objectively measured edema, neither the VEINES-QOL/
Sym nor the SF-36 shows responsiveness to clinical change.
DISCUSSION
Comprehensive assessment of quality of life should
include both generic and disease-specific measures that are
reliable, valid and responsive.2,11,12 The VEINES-QOL/
Sym is a practical and scientifically sound, patient-reported
disease-specific measure of outcome in CVDL that meets
standard criteria for acceptability, reliability, validity, and
responsiveness. As the only fully validated measure of qual-
ity of life and symptoms in CVDL that is appropriate for use
across the full spectrum of CVDL-related conditions, is
quick and easy to administer, and is available in English and
three other languages, the VEINES-QOL/Sym provides a
rigorous method for improving the evaluation of outcomes
in clinical trials and audit. As a short questionnaire that
takes less than 10 minutes to complete, it can be easily
incorporated into clinical trials, epidemiologic studies, and
routine audit.
This new outcome measure offers a valuable tool for
evaluation of the efficacy of new treatments for CVDL
because it provides evidence that will be scientifically cred-
ible to regulatory bodies, clinicians, researchers, and patient
advocacy groups. It will be particularly important in evalu-
ation of outcomes in clinical trials of new drug treatments
because decisions about licensing and reimbursement now
require the kind of rigorous evidence about patient-re-
ported outcomes provided by the VEINES-QOL/Sym.
CVDL is associated with significant disease burden in
terms of pain and suffering, loss of mobility, impairment of
function at work and at home, and psychological distress.
However, research on these important patient-reported
outcomes has been limited by the lack of suitable or scien-
tifically rigorous measures of outcome in CVDL. Although
generic measures, such as the SF-36, have proven to be
useful, results from this study clearly show the superiority of
the disease-specific VEINES-QOL/Sym in detection of
clinical improvement. As a more responsive instrument
than the SF-36, the VEINES-QOL/Sym holds promise in
evaluation of new treatments whose impact may not be
detected with less sensitive generic measures.
Although there are well-validated condition-specific
measures for varicose veins13,15 and ulcers,18 and for re-
lated conditions such as deep vein thrombosis,50 there is
the need for an outcome measure that is suitable for use
across the full spectrum of CVDL-related conditions. The
VEINES-QOL/Sym is the only English-language CVDL-
specific measure that is suitable for use across the range of
CVDL-related conditions. It therefore permits evaluation
of the comparative impact of different clinical manifesta-
tions of CVDL, such as ulcers and varicose veins, on quality
of life and symptoms in the same study or across studies.
Because it is also available in three additional validated
language versions, the VEINES-QOL/Sym is particularly
well suited for use in international epidemiologic studies
and clinical trials.
The VEINES-QOL/Sym has applications in both re-
search and routine monitoring of healthcare. As an out-
come measure in clinical trials, it will provide scientifically
Table VII. Responsiveness of VEINES-QOL/Sym:
mean change scores between baseline and final
assessments
Clinical outcome
Clinically
improved
(n)*
Clinically
unimproved
(n)* P value
Clinically measured varicose veins†
VEINES-QOL –1.44 (80) 0.29 (810) .001
VEINES-Sym –1.66 (79) 0.28 (796) .003
SF-36 PCS –0.44 (65) 0.22 (664) .50
SF-36 MCS –1.30 (65) –0.50 (664) .55
Varicose vein–related pain†
VEINES-QOL –0.87 (129) 1.20 (162) .000
VEINES-Sym –0.61 (127) 1.40 (156) .002
SF-36 PCS 0.66 (102) 1.22 (130) .57
SF-36 MCS –2.49 (102) 0.66 (130) .02
Clinically measured edema†
VEINES-QOL –0.41 (175) 0.89 (295) .005
VEINES-Sym –0.53 (173) 1.21 (286) .002
SF-36 PCS –0.87 (145) 0.60 (236) .07
SF-36 MCS –0.08 (145) 0.30 (236) .72
Objectively (Leg-O-Meter)
measured edema†
VEINES-QOL –0.009 (56) 0.80 (225) .29
VEINES-Sym 0.39 (57) 0.85 (218) .62
SF-36 PCS –1.49 (49) 0.25 (185) .17
SF-36 MCS 2.06 (49) –0.41 (185) .17
CEAP score‡
VEINES-QOL 0.74 (183) –0.11 (1034) .02
VEINES-Sym 0.78 (181) –0.15 (1018) .04
SF-36 PCS 1.27 (167) –0.22 (867) .02
SF-36 MCS –1.44 (167) –0.36 (867) .20
*Sample sizes vary because target clinical conditions used to evaluate im-
provement were relevant only to subsample of patients who had target
condition.
†Negative change scores indicate improvement.
‡Positive change scores indicate improvement.
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credible information about the efficacy of treatment from
the patient’s point of view. When combined with informa-
tion about clinical outcomes and costs, rigorous data about
important patient-reported outcomes, such as quality of life
and symptoms, allow the type of comprehensive evaluation
advocated for new treatments in all areas of healthcare.51
Routine use of the VEINES-QOL/Sym in clinical audit
will enable clinicians and managers to evaluate outcomes
on a continuing basis. Such information can be used to
improve practice by identifying strengths and deficiencies
in quality of care.
Our conclusions about the acceptability, reliability, va-
lidity, and responsiveness of the VEINES-QOL/Sym are
based on the results of field testing in a sample of more than
1600 patients with a broad spectrum of CVDL-related
disorders in four countries. Our findings are based on a
large, population-based sample of randomly selected pa-
tients with self-reported symptoms that is likely to be
representative of CVDL in the community. One limitation
of the VEINES sample is that despite intentional oversam-
pling of men and limbs with ulceration, the sample re-
mained skewed toward women (78%) and less severe forms
of CVDL. This potential sampling bias is, however, of less
concern in a psychometric study than in an epidemiologic
study. Testing of the VEINES QOL/Sym in other studies
would be useful to confirm the psychometric properties of
the new measure in independent samples. Another limita-
tion is that case definition and the assessment of clinical
outcomes in the VEINES study were with clinical exami-
nation without anatomic confirmation of a venous compo-
nent.
Further evaluation of the ability of the VEINES-QOL/
Sym to detect changes in outcome following different
treatments of known efficacy would provide useful evidence
of responsiveness to specific interventions. Future work
should be undertaken to investigate the suitability and
psychometric performance of the VEINES-QOL/Sym for
use in related conditions, such as deep vein thrombosis, and
to compare this new all-purpose CVDL measure with ex-
isting condition-specific measures of varicose veins and
ulcer-specific measures in these two patient groups. Subse-
quent studies are also needed to establish population norms
in different countries, so that the appropriate population-
based weights can be used in place of current sample-
specific scoring algorithms and to determine how VEINES-
QOL/Sym scores map on meaningful clinical differences.
Finally, the test-retest reliability of the Italian and French-
Canadian versions and the responsiveness of the four indi-
vidual language versions of the VEINES-QOL/Sym need
further evaluation.
A copy of the VEINES-QOL/Sym and the SPSS scor-
ing program (please provide a blank floppy disk) can be
obtained from Dr Lamping.
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APPENDIX, ONLINE ONLY
VEINES-QOL
Many people in Canada complain about leg problems.
In this survey, we are interested in finding out more about
the effects of your leg problem on your daily activities, both
at home and at work. This information will give us a better
idea about how to treat such problems.
Thank you for participating in this study. This ques-
tionnaire includes questions about your health in general
and about your leg problem, as well as questions about your
life and usual activities. It will take about 10 minutes to
complete. All of your answers are confidential. Do not write
your name on the questionnaire.
Please answer every question. If you wish to check or
change any answer after you have returned your completed
questionnaire, please contact either your doctor or Mrs. X
at the address below. She is in charge of the survey.
After you have completed the questionnaire, please
return it to us by mail in the envelope provided to you or
give it to your doctor at the next visit.
Thank you for your help.
For additional information please contact:
Mrs.X
Address:
te´l.:



